CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR

• Main Authors: PURRO NORBERT, SMYTH MARK, GOLDMAN ERICK, WIRTH DAVID D
• Format: Patent
• Language: English; Korean
• Published: 18.12.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

본원에 개시된 것은 브루톤 타이로신 키나아제(Bruton's tyrosine kinase; Btk) 저해제 1-((R)-3-(4-아미노-3-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-1-일)피페리딘-1-일)프로프-2-엔-1-온이며, 이것은 이의 결정 형태, 용매화물 및 약학적으로 허용가능한 염을 포함한다. 또한 개시된 것은 Btk 저해제를 포함하는 약학 제제와, Btk 저해제를 단독으로 또는 다른 치료제와 조합하여 이용하는 방법인데, 이는 자가면역 질환 또는 병태, 이종면역 질환 또는 병태, 림프종을 포함하는 암, 및 염증성 질환 또는 병태의 치료를 위한 것이다. Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.